• Abhinav Singla, Christopher V Anstine, Linda Huang, Jordan K Rosedahl, Arya B Mohabbat, and Lindsey M Philpot.
• Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: singla.abhinav@mayo.edu.
• Mayo Clin. Proc. 2024 Apr 1; 99 (4): 542550542-550.

ObjectiveTo assess the use of cannabis as a symptom management strategy for patients with fibromyalgia.Patients And MethodsAn electronic, cross-sectional survey was conducted among patients diagnosed with fibromyalgia and treated in Integrative Medicine & Health at Mayo Clinic, Rochester, Minnesota. The survey was constructed with the Symptom Management Theory tool and was sent anonymously via web-based software to patients with a diagnosis of fibromyalgia.ResultsOf 5234 patients with fibromyalgia sent the online survey, 1336 (25.5%) responded and met the inclusion criteria. Survey respondents had a median age of 48 (Q1-Q3: 37.5-58.0) years, and most identified as female. Nearly half of respondents (49.5%, n=661) reported cannabis use since their fibromyalgia diagnosis. The most common symptoms for which respondents reported using cannabis were pain (98.9%, n=654); fatigue (96.2%; n=636); stress, anxiety, or depression (93.9%; n=621); and insomnia (93.6%; n=619). Improvement in pain symptoms with cannabis use was reported by 82.0% (n=536). Most cannabis-using respondents reported that cannabis also improved symptoms of stress, anxiety, and depression and of insomnia.ConclusionConsidering that cannabis is a popular choice among patients for managing fibromyalgia symptoms, clinicians should have adequate knowledge of cannabis when discussing therapeutic options for fibromyalgia with their patients.Copyright © 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

15 keywords...

hide…